[Delayed therapy of clinically localized prostatic carcinoma. Experiences of the Karolinska Hospital].
From 1978 to 1982, 172 patients with T1-3, Nx, M0 prostate cancer were included in a surveillance protocol with deferred treatment on symptomatic progression. The median age at diagnosis was 68 (38-89) years. The disease-specific survival at 10 years was 80% for the total series, 84% for the subgroup with T1-2 tumors, and 92% for patients with T1-2 tumors diagnosed when the patients were old less than 70 years. For the subgroup with T3 tumors, the disease-specific survival at 9 years was 70%. In all subgroups the competing mortality was higher than the prostate cancer mortality. Deferred treatment appears to be an acceptable treatment option for patients with a tumor clinically confined to the prostate with a life expectancy of 10 years or less.
Adolfsson
J
J
Abteilung für Urologie, Karolinska-Krankenhaus, Stockholm, Schweden.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002423:Cause of Death; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology
Verzögerte Therapie des klinisch lokal begrenzten Prostatakarzinoms. Erfahrungen am Karolinska-Krankenhaus.